Home Newsfeeds ‘Pinterest launches its collage-making app Shuffles to the general public’ – TechCrunch

News

‘Pinterest launches its collage-making app Shuffles to the general public’ – TechCrunch

https://techcrunch.com/2022/11/10/pinterest-launches-its-collage-making-app-shuffles-to-the-general-public/?tpcc=tcplustwitter

byBenzinga Newsdesk

November 10, 2022

1 minute read

Pinterest launches its collage-making app Shuffles to the general public

News

Acutus Medical Achieves OEM Qualification Milestone In Sale of Left-Heart Access Portfolio To Medtronic

By Benzinga Newsdesk

November 3, 8:11 AM

Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that

AFIB

Coinbase Stock Drops to New Low, Down 87% Since Start Of 2022

By Murtuza Merchant

December 21, 1:52 PM

Coinbase (NASDAQ: COIN) stock dropped a whopping 87.04% to $35.00 levels from $268.15 on Dec.

COIN

IN8bio Highlights Recent Company Accomplishments And Outlines 2024 Pipeline Goals

By Benzinga Newsdesk

January 4, 9:30 AM

Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65th American Society of Hematology

INAB

Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate

By Benzinga Newsdesk

November 10, 5:13 PM

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share

RGLS

‘Pinterest launches its collage-making app Shuffles to the general public’ – TechCrunch

Related Posts

Acutus Medical Achieves OEM Qualification Milestone In Sale of Left-Heart Access Portfolio To Medtronic

Coinbase Stock Drops to New Low, Down 87% Since Start Of 2022

IN8bio Highlights Recent Company Accomplishments And Outlines 2024 Pipeline Goals

Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate